{"id":"adalimumab-us","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"10%","effect":"Headache"},{"rate":"10%","effect":"Fatigue"},{"rate":"10%","effect":"Muscle pain"},{"rate":"5%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Adalimumab is a fully human monoclonal antibody that selectively binds to tumor necrosis factor-alpha (TNF-alpha) and inhibits its interaction with cell surface TNF receptors. This action prevents TNF-alpha from inducing inflammation and cell death.","oneSentence":"Tumor necrosis factor-alpha inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T05:49:32.106Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid Arthritis"},{"name":"Psoriatic Arthritis"},{"name":"Ankylosing Spondylitis"},{"name":"Crohn's Disease"},{"name":"Ulcerative Colitis"}]},"trialDetails":[{"nctId":"NCT04372108","phase":"","title":"A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis","status":"RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2021-06-24","conditions":"Crohn Disease, Colitis, Ulcerative","enrollment":1056},{"nctId":"NCT05108259","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects","status":"RECRUITING","sponsor":"Prestige Biopharma Limited","startDate":"2022-03-30","conditions":"Healthy Volunteers","enrollment":324},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT05073315","phase":"PHASE3","title":"A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Amgen","startDate":"2021-10-04","conditions":"Plaque Psoriasis","enrollment":425},{"nctId":"NCT03849313","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2019-03-20","conditions":"Healthy Volunteers","enrollment":390},{"nctId":"NCT02472912","phase":"PHASE1","title":"Adalimumab PK Bioequivalence Study to EU and US Sourced Humira","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-12","conditions":"Healthy Volunteers","enrollment":270},{"nctId":"NCT03970824","phase":"PHASE1","title":"To Compare the Pharmacokinetics and Safety of CT-P17 and Humira in Healthy Subjects","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-05-31","conditions":"Healthy","enrollment":312},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT03014947","phase":"PHASE1","title":"MSB11022 in Healthy Subjects","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2014-05","conditions":"Healthy Subjects","enrollment":237},{"nctId":"NCT01505491","phase":"PHASE1","title":"Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-12-01","conditions":"Healthy","enrollment":193},{"nctId":"NCT02744755","phase":"PHASE3","title":"Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2016-03-31","conditions":"Rheumatoid Arthritis","enrollment":353},{"nctId":"NCT02786563","phase":"","title":"Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate","status":"WITHDRAWN","sponsor":"AbbVie","startDate":"2018-09-30","conditions":"Rheumatoid Arthritis (RA)","enrollment":""},{"nctId":"NCT02144714","phase":"PHASE1","title":"Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2014-05","conditions":"Healthy","enrollment":189},{"nctId":"NCT02045979","phase":"PHASE1","title":"Pharmacokinetics and Safety in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-01-31","conditions":"Healthy","enrollment":327},{"nctId":"NCT02137226","phase":"PHASE3","title":"BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2015-01-26","conditions":"Arthritis, Rheumatoid","enrollment":645},{"nctId":"NCT00775437","phase":"PHASE3","title":"Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2009-03","conditions":"Juvenile Idiopathic Arthritis","enrollment":32},{"nctId":"NCT02237729","phase":"PHASE1","title":"A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-09","conditions":"Healthy Subjects","enrollment":362},{"nctId":"NCT01870986","phase":"PHASE1","title":"Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-05","conditions":"Healthy","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Adalimumab-US","genericName":"Adalimumab-US","companyName":"Pfizer","companyId":"pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tumor necrosis factor-alpha inhibitor Used for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}